Aurinia Pharmaceuticals (AUPH) Share-based Compensation (2020 - 2026)

Aurinia Pharmaceuticals has reported Share-based Compensation for 7 years, with the latest figure at -$866000.0 in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 74.6% year-over-year to -$866000.0; the trailing twelve-month figure through Mar 2026 stood at $17.2 million (down 23.29% YoY), and the FY2025 full-year result was $14.7 million, down 53.54% from the prior year.
• Share-based Compensation for Q1 2026 stood at -$866000.0, down from $6.7 million in the prior quarter.
• The five-year high for Share-based Compensation was $12.3 million in Q2 2023, with the low at -$3.4 million in Q1 2025.
• Historically, Share-based Compensation has averaged $7.2 million across 5 years, with a median of $8.3 million in 2022.
• Annual changes were most pronounced in 2025 — Share-based Compensation plunged 159.42% — and 2026, when it surged 74.6%.
• Aurinia Pharmaceuticals' Share-based Compensation stood at $6.9 million in 2022, then surged by 70.5% to $11.8 million in 2023, then fell by 23.98% to $8.9 million in 2024, then decreased by 24.79% to $6.7 million in 2025, then plunged by 112.87% to -$866000.0 in 2026.
• The last three Share-based Compensation figures came in at -$866000.0 (Q1 2026), $6.7 million (Q4 2025), and $5.9 million (Q3 2025), per Business Quant data.